USPTO grant strengthens Alterity’s IP position and opens a path for ATH434 into Parkinson’s disease investment.
Patents rarely make headlines outside the biotech trade press, but for a clinical-stage company preparing to enter a pivotal trial, a strong patent estate can matter as much as the data itself.
Alterity Therapeutics has just secured one of those consequential wins: a new US composition-of-matter patent for ATH434, its lead candidate for Multiple System Atrophy (MSA), that pushes exclusivity protection out to at least 2045 [1].
The California-based company is preparing to initiate Phase 3 trial activities in MSA by the end of 2026, and investors evaluating clinical-stage neurodegeneration companies increasingly weigh intellectual property runway alongside efficacy data. A two-decade patent horizon changes the calculus for potential partners and licensees, and it gives Alterity a stronger hand heading into any future negotiations.
The United States Patent and Trademark Office granted Alterity a patent titled Crystalline Form, and Process for its Production, which protects the specific crystalline structure of the mesylate salt form of ATH434, along with methods for using it to treat neurological conditions. This is not a peripheral formulation tweak. The mesylate salt form was the version used in Alterity’s Phase 2 trials and is the form slated for the Phase 3 programme, meaning the patent protects the exact molecule moving through clinical development rather than a variant that might never reach patients.
Composition-of-matter claims are generally considered the strongest tier of pharmaceutical patent protection, harder to design around than method-of-use or formulation patents. The company expects the patent to eventually be listed in the FDA’s Orange Book once ATH434 receives regulatory approval, which would provide an additional layer of commercial protection beyond the patent term itself.
Drug development in Parkinsonian disorders is a long and capital-intensive game. MSA alone affects up to 50,000 people in the US, and there are currently no therapies that slow disease progression, only treatments that manage individual symptoms. Bringing a disease-modifying therapy to market typically requires sustained investment across years of trials, and investors want assurance that a company will be able to capture the commercial value of a successful outcome once it arrives.
Alterity’s CEO, David Stamler, framed the patent as validation of a deliberate IP strategy rather than a one-off event, noting that the extended protection window supports the company’s ability to justify further investment in additional indications. Patents do not just protect existing programmes; they can unlock new ones.
ATH434 was developed to reduce iron accumulation and inhibit abnormal protein aggregation in the brain, mechanisms implicated in a range of neurodegenerative conditions beyond MSA. With composition-of-matter protection now secured to 2045, Alterity says Parkinson’s disease has become a “viable target indication” for the same compound, since the strengthened IP provides the commercial protection needed to justify expanding development into a much larger patient population.
Parkinson’s disease affects nearly one million people in the US and more than ten million worldwide, a market considerably larger than the rare-disease MSA population that has been Alterity’s primary focus to date.
This is a common pattern in neurodegeneration drug development: a compound proven in a smaller, well-defined orphan population becomes the foundation for a broader push into a related but far larger disease category, provided the patent runway and regulatory designations support the additional investment required.
ATH434 already carries FDA Fast Track designation and Orphan Drug designation in both the US and Europe for MSA, and Alterity’s Phase 2 data, a randomised, double-blind, placebo-controlled trial reinforced by a second open-label biomarker study in more advanced MSA patients, demonstrated clinically meaningful efficacy alongside target engagement biomarkers and a favourable safety profile. The Phase 3 pivotal trial, expected to begin by year-end 2026, will be the true test of whether those early signals translate into a therapy that can slow disease progression in a rigorously controlled setting.
Extending healthspan is also about developing therapies for the diseases that most severely compress quality of life in later years. Neurodegenerative disorders like MSA and Parkinson’s disease strip away independence and mobility well before life itself ends, making them a central target for the longevity field’s broader goal of extending not just lifespan, but the years lived in good health. A stronger patent position for ATH434 does not change the biology, but it materially improves the odds that a disease-modifying treatment for these conditions actually reaches the patients who need it.
